Brief: Sio Gene Therapies Announces Positive Six-Month Follow-Up Data From Low-Dose Cohort Of Phase 1/2 Trial Of Axo-Aav-Gm1 For Gm1 Gangliosidosis

Sio Gene Therapies

15/12/2020 21:39

Dec 15 (Reuters) - Sio Gene Therapies Inc  SIOX.O :
    * SIO GENE THERAPIES ANNOUNCES POSITIVE SIX-MONTH FOLLOW-UP
DATA
FROM LOW-DOSE COHORT OF PHASE 1/2 TRIAL OF  AXO-AAV-GM1 FOR GM1
GANGLIOSIDOSIS
    * SIO GENE THERAPIES INC - GENERALLY WELL-TOLERATED WITH A
FAVORABLE SAFETY PROFILE IN FIVE PATIENTS
    * SIO GENE THERAPIES INC - SERUM BETA-GALACTOSIDASE ENZYME
ACTIVITY INCREASED IN ALL PATIENTS AT ALL TIMEPOINTS BETWEEN DAY
7 AND MONTH 6
    * SIO GENE THERAPIES INC - AT MONTH 6, ENZYME ACTIVITY
RESTORED TO
23-57% (MEAN: 38%) OF NORMAL REFERENCE LEVELS
    * SIO GENE THERAPIES INC - ALL FIVE CHILDREN DEMONSTRATED
SIGNS OF
CLINICAL DISEASE STABILITY
    * SIO GENE THERAPIES INC - HIGH-DOSE COHORT INITIATED IN
NOVEMBER
2020; TWO PATIENTS NOW DOSED WITHOUT COMPLICATIONS

Source text for Eikon:  ID:nGNX9rJSVT 
Further company coverage:  SIOX.O 

 ((Reuters.Briefs@thomsonreuters.com;))